Evo Visian Implantable Collamer Lenses (ICL) can now extend to patients between the ages of 21 and 60 years old. Its previous indication covered patients between 21 and 45. The expanded approval comes on the heels of three-year clinical data that reinforces the long-term safety profile of EVO ICL.

Lake Forest, California-based Staar says the expansion helps further increase the addressable market for EVO in the U.S.

EVO ICL preserves corneal tissue and the eye’s natural crystalline lens. It offers a reversible, lens-based approach to vision correction that maintains future treatment flexibility. The company designed it to support long-term vision care and allow surgeons to tailor future solutions as needs evolve over time.